Delving into the Latest Updates on Eciskafusp alfa(Roche) with Synapse

Overview

Basic Info

Drug Type

Antibody fusion proteins

Synonyms

+ [1]

Target

IL-2R x PD-1

Action

agonists, inhibitors

Mechanism

IL-2R agonists(Interleukin-2 receptor agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Non-Muscle Invasive Bladder NeoplasmsSolid tumor

Inactive Indication-

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

Hoffmann-La Roche Ltd.

Roche Holding AG

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 317222146

Source: *****

Sequence Code 315618112L

Source: *****

Sequence Code 315618109H

Source: *****

The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with BCG in participants with BCG-unresponsive high-risk NMIBC.
The study plans a similar evaluation of eciskafusp alfa in monotherapy following a positive interim analysis of the combination therapy.

Start Date15 May 2025

Sponsor / Collaborator

Hoffmann-La Roche Ltd.

NCT04303858

/ Active, not recruitingPhase 1

An Open-Label, Multicenter, Randomized, Dose-Escalation and Extension, Phase IA/IB Study to Evaluate Safety and Anti-Tumor Activity of RO7284755, A PD-1 Targeted IL-2 Variant (IL-2V) Immunocytokine, Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint inhibition blockade. The maximum duration in the study for each participant will be up to 28 months.

Start Date04 May 2020

Sponsor / Collaborator

Roche Holding AG

100 Clinical Results associated with Eciskafusp alfa(Roche)

Login to view more data

100 Translational Medicine associated with Eciskafusp alfa(Roche)

Login to view more data

100 Patents (Medical) associated with Eciskafusp alfa(Roche)

Login to view more data

2

Literatures (Medical) associated with Eciskafusp alfa(Roche)

31 Dec 2023·OncoImmunology

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

Article

Author: Klein, Christian ; Umaña, Pablo ; Codarri Deak, Laura ; Hashimoto, Masao

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1⁺ T-cells and acts on antigen-specific stem-like PD-1⁺ TCF-1⁺ CD8⁺ T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.

IL15/IL15Rα complex induces an anti-tumor immune response following radiation therapy only in the absence of Tregs and fails to induce expansion of progenitor TCF1+ CD8 T cells

Article

Author: Karam, Sana D ; Zhu, Yuwen ; Knitz, Michael ; Yee, Elliot ; Larson, Keira Y. ; Amann, Maria ; Larson, Keira Y ; Gadwa, Jacob ; Karam, Sana ; Saviola, Anthony ; Klein, Christian ; Hodgson, Chloe ; Piper, Miles ; Yee, Elliott

AbstractBackgroundThis work seeks to understand whether IL15-incorporating treatments improve response to radiotherapy and uncover mechanistic rationale for overcoming resistance to IL15 agonism using novel therapeutic combinations.Experimental DesignOrthotopic tumor models of PDAC were used to determine response to treatment. IL15-/- and Rag1-/- mouse models were employed to determine dependence on IL15 and CTLs, respectively. Flow cytometry was used to assess immune cell frequency and activation state. Phospho-proteomic analyses were used to characterize intracellular signaling pathways.ResultsWe show that the combination of radiation therapy (RT) and an IL15/IL15Ra fusion complex (denoted IL15c) fails to confer anti-tumor efficacy; however, a CD8-driven anti-tumor immune response is elicited with the concurrent administration of an aCD25 Treg-depleting antibody. Using IL15-/- and Rag1-/- mice, we demonstrate that response to RT + IL15c + aCD25 is dependent on both IL15 and CTLs. Furthermore, despite an equivalent survival benefit following treatment with RT + IL15c + aCD25 and combination RT + PD1-IL2v, a novel immunocytokine with PD-1 and IL2Rβγ binding domains, CTL immunophenotyping and phospho-proteomic analysis of intracellular metabolites showed significant upregulation of activation and functionality in CD8 T cells treated with RT + PD1-IL2v. Finally, we show the immunostimulatory response to RT + PD1-IL2v is significantly diminished with a concurrent lack of TCF+ CD8 T cell generation in the absence of functional IL15 signaling.ConclusionsOur results are illustrative of a mechanism wherein unimpeded effector T cell activation through IL2Rβ signaling and Treg inhibition are necessary in mediating an anti-tumor immune response.

100 Deals associated with Eciskafusp alfa(Roche)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	Phase 1	Spain	Hoffmann-La Roche Ltd.	15 May 2025
Non-Muscle Invasive Bladder Neoplasms	Phase 1	Australia	Hoffmann-La Roche Ltd.	15 May 2025
Non-Muscle Invasive Bladder Neoplasms	Phase 1	Netherlands	Hoffmann-La Roche Ltd.	15 May 2025
Non-Muscle Invasive Bladder Neoplasms	Phase 1	Poland	Hoffmann-La Roche Ltd.	15 May 2025
Solid tumor	Phase 1	Canada	Roche Holding AG	04 May 2020
Solid tumor	Phase 1	Poland	Roche Holding AG	04 May 2020
Solid tumor	Phase 1	Spain	Roche Holding AG	04 May 2020
Solid tumor	Phase 1	Netherlands	Roche Holding AG	04 May 2020
Solid tumor	Phase 1	Denmark	Roche Holding AG	04 May 2020
Solid tumor	Phase 1	Belgium	Roche Holding AG	04 May 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data